Pulmonary hypertension in advanced heart failure

Herz

Volumn 30, Issue 4, 2005, Pages 311-317

  Ghio, Stefano ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Heart failure; Pulmonary hypertension; Right ventricle

Indexed keywords

BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; PROSTACYCLIN;

ARTICLE; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; DRUG FATALITY; FLUID RETENTION; HEART CATHETERIZATION; HEART FAILURE; HEART RIGHT VENTRICLE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; LUNG CIRCULATION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT CONTRAINDICATION;

BLOOD PRESSURE DETERMINATION; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY;

EID: 21544472356     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2696-3     Document Type: Article

References (46)

1. Abramson SV, Burke JF, Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992;116:888-95.
2. Anguita M, Arizon JM, Bueno G, et al. Clinical and hemodynamic predictors of survival in patients aged < 65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1993;72:413-7.
3. Baker BJ, Wilen MM, Boyd CM, et al. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol 1984;54:596-9.
4. Blitzer ML, Loh E, Roddy MA, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996;28:591-6.
5. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999;34:1802-6.
6. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
7. Capomolla S, Febo O, Guazzotti G, et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 2000;19:426-38.
8. Capomolla S, Febo O, Opasich C, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001;3:601-10.
9. Cappola TP, Felker GM, Kao WHL, et al. Pulmonary hypertension and risk of death in cardiomyopathy. Patients with myocarditis are at higher risk. Circulation 2002;105:1663-8.
10. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium- dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-6.
11. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996;28:1092-102.
12. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
13. Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998;82:609-14.
14. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48-54.
15. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995;25:1143-53.
16. Drazner MH, Hamilton MA, Fonarow G, et al. Relationship between right and left-sided filling pressure in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999;18:1126-32.
17. Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996;94:1578-84.
18. Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997;29:153-9.
19. Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricularfailure. Am Heart J 1985;110:807.
20. Gavazzi A, Ghio S, Scelsi L, et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 2003;145:310-6.
21. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:183-8.
22. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;106:473-8.
23. Givertz MM, Colucci WS, LeJemtel TH, et al., on behalf of the Study Investigators. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101:2922.
24. Grant SCD, Levy RD, Brooks NH. Fall in pulmonary vascular resistance in patients awaiting heart transplantation. Br Heart J 1992;68:365-8.
25. Hülsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998;32:1695-700.
26. Kalra PR, Moon JCC, Coats JS. Do results of ENABLE (Endothelin Antagonist Bosentan for Lowering cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7.
27. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990;65:903-8.
28. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation - a preliminary study. Eur J Cardiothorac Surg 2004;25:971-7.
29. Masaki T. The discovery of endothelins. Cardiovasc Res 1998;39:530-3.
30. Mikhail G, Chester AH, Gibbs SR, et al. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol 1998;82:254.
31. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure. The role of the endothelium in pathophysiology and management. Circulation 2000;102:1718-23.
32. Morley D, Brozena SC. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol 1994;73:379-83.
33. Naije R, Lipski A, Abramowicz M, et al. Nature of pulmonary hypertension in congestive heart failure. Effect of cardiac transplantation. Am J Respir Crit Care Med 1994;149:881-7.
34. Node K, Kitakaze M, Yoshihara F, et al. Increased cardiac levels of nitric oxide in patients with chronic heart failure. Am J Cardiol 2000;86:474.
35. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-804.
36. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sixtasentan. Circulation 2002;106:1618-21.
37. Pinamonti B, Di Lenarda A, Sinagra G, et al. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993;22:808-15.
38. Porter TR, Taylor DO, Cycan A, et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 1993;22:1418-24.
39. Pozzoli M, Traversi E, Cioffi G, et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997;95:1222-30.
40. Rodeheffer RJ, Lerman A, Heublein DM, et al. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-24.
41. Saxon LA, Stevenson WG, Middlekauff HR, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1993;72:62-5.
42. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035-40.
43. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990;66:1348-54.
44. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995;26:1417-23.
45. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
46. Tsutamoto Y, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.